Study suggests immune system plays role in extended PFS in MM

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and other top-tier cancer centers highlights the vital role that the immune system plays in determining the duration of patients’ remission from multiple myeloma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

MAIA Biotechnology Inc. and BeiGene entered into a clinical supply agreement to assess the efficacy of THIO, MAIA Biotechnology’s small molecule telomere-targeting anticancer agent, in combination with BeiGene’s immune checkpoint inhibitor tislelizumab, in three cancer indications. The single-arm pivotal phase II trials will study the drug combination in hepatocellular carcinoma, small cell lung cancer, and colorectal cancer.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login